2022年4月5日 · The use of 340B pricing grew in 2010 when Congress implemented an expansion of covered entity eligibility, allowing more providers to enter the program 3, and regulators opened the door for those providers to work with an unlimited number of 340B contract pharmacies to distribute drugs. 4 ; In 2018 alone, the 340B Program processed about $94 ...

administered drugs and $41 for physician-administered drugs. • Taking into account the 340B program (scenario 2), there was a 4.2% increase in drug costs versus scenario 1. • If expanded 340B eligibility was considered (scenario 3), drug costs increased 8.4% versus scenario 1. • The 340B Drug Discount Program is a $124B federal program in ...

In the proposed rule, CMS states its intent to make significant changes to the Calendar Year (CY) 2023 payment rate for drugs purchased through the 340B program. Since 2018, CMS has paid for non-pass-through drugs and biologics acquired under 340B prices at …

The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.

2024年12月11日 · 340B News | November 7, 2023. NPC's John O'Brien shared perspectives with the 340B Report's Tom Mirga about CMS' proposal to redefine Medicaid Best Price, which is used to calculate 340B discounts and is included in CMS' Medicaid Drug Rebate Program (MDRP) proposed regulation. Read here (subscription required 🔒)

Ted Slafsky, Publisher and CEO, 340B Report; The 340B drug pricing program remains a complex and evolving issue, impacting a wide range of stakeholders across the healthcare landscape. This session will provide an overview of how the program operates and its impact on key stakeholders, including covered entities, contract pharmacies, and payers.

2024年12月11日 · The Cost of the 340B Program Part 1 & Part 2 – NPC supported these reports published by IQVIA examining the hidden costs of the 340B program to employers. Health costs increased for self-insured employers and their employees by …

2020年7月20日 · Under current regulations, the ceiling price for a drug under the 340B program is tied to the Medicaid drug rebate amount. This rebate amount, in turn, is impacted by Medicaid Best Price. NPC recommends that CMS, in conjunction with the Health Resources and Services Administration (HRSA), clarify that policies for 340B will remain consistent.

After Independence Blue Cross’ January 2025 drug coverage policy update to exclude non-oncology drugs from reimbursement within 18 months of accelerated drug approval, NPC researchers analyzed the FDA accelerated approval program drug list at different timeframes to understand the ongoing accelerated approval drug mix by therapeutic area for ...

2024年8月13日 · For immediate release: August 13, 2024 Contact: Michael Pratt, 202-827-2088, [email protected] Washington, DC – Today in the American Journal of Managed Care, NPC’s Julie Patterson, John M. O’Brien, and Jon D. Campbell author a new analysis supporting the FDA’s conclusion that the Accelerated Approval (AA) Program is successfully working to address …